Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/a-phase-ii-open-label-study-of-the-intravenous-administration-of-FxNGc0HTa7
References (62)
-
P. Fenaux, G. Mufti, E. Hellstrom-Lindberg, V. Santini, C. Finelli, A. Giagounidis, R. Schoch, N. Gattermann, G. Sanz, A. List, S. Gore, J. Seymour, J. Bennett, J. Byrd, J. Backstrom, L. Zimmerman, D. McKenzie, C. Beach, L. Silverman (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.The Lancet. Oncology, 10 3
-
S. Obrien, A. Keating, H. Kantarjian, M. Talpaz, M. Beran, S. Stass, M. Rios, W. Plunkett (1993)
Homoharringtonine induces apoptosis in chronic myelogenous leukemia‐cellsBlood, 82
-
E. Feldman, Z. Arlin, T. Ahmed, A. Mittelman, C. Puccio, H. Chun, P. Cook, P. Baskind (1992)
Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.Leukemia, 6 11
-
Y. Li, S. Guo, F. Zhou, S. Xu, H. Zhang (1983)
Combined harringtonine or homoharringtonine chemotherapy for acute nonlymphocytic leukemia in 25 children.Chinese medical journal, 96 4
-
Vincent Levy, Sarah Zohar, C. Bardin, A. Vekhoff, D. Chaoui, B. Rio, O. Legrand, S. Sentenac, P. Rousselot, E. Raffoux, F. Chast, Sylvie Chevret, J. Marie (2006)
A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemiaBritish Journal of Cancer, 95
-
J. Grem, B. Cheson, S. King, B. Leyland-Jones, M. Suffness (1988)
Cephalotaxine esters: antileukemic advance or therapeutic failure?Journal of the National Cancer Institute, 80 14
-
H. Kantarjian, M. Talpaz, V. Santini, A. Murgo, B. Cheson, S. O'brien (2001)
Homoharringtonine: history, current research, and future direction.Cancer, 92 6
-
Mou-Tuan Huang (1975)
Harringtonine, an inhibitor of initiation of protein biosynthesis.Molecular pharmacology, 11 5
-
Cephalotaxus Research Coordinating Group (1976)
263Chinese Medical Journal, 2
-
E. Jabbour, G. Garcia-Manero, N. Batty, Jenny Shan, S. O'brien, J. Cortes, F. Ravandi, J. Issa, H. Kantarjian (2010)
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapyCancer, 116
-
D. Baaske, P. Heinstein (1977)
Cytotoxicity and Cell Cycle Specificity of HomoharringtonineAntimicrobial Agents and Chemotherapy, 12
-
C. Cutler, Stephanie Lee, P. Greenberg, H. Deeg, W. Pérez, C. Anasetti, B. Bolwell, M. Cairo, R. Gale, J. Klein, H. Lazarus, J. Liesveld, P. McCarthy, G. Milone, J. Rizzo, K. Schultz, M. Trigg, A. Keating, D. Weisdorf, J. Antin, M. Horowitz (2004)
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.Blood, 104 2
-
Yinjun Lou, Jin Jie, Weilai Xu, Xiangming Tong (2004)
Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro‐apoptotic bax and inducing caspase‐3‐mediated cleavage of poly(ADP‐ribose) polymerase (PARP)American Journal of Hematology, 76
-
Ajani (1986)
375Cancer Treatment Reports, 70
-
Chun-kang Chang, B. Storer, B. Storer, Bart Scott, Bart Scott, Eileen Bryant, Eileen Bryant, Howard Shulman, Howard Shulman, M. Flowers, M. Flowers, B. Sandmaier, B. Sandmaier, R. Witherspoon, R. Witherspoon, Richard Nash, Richard Nash, J. Sanders, J. Sanders, Antonio Bedalov, A. Bedalov, J. Hansen, J. Hansen, B. Clurman, B. Clurman, R. Storb, R. Storb, F. Appelbaum, F. Appelbaum, H. Deeg, H. Deeg (2007)
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders.Blood, 110 4
-
Zhou (1990)
2031Cancer Research, 50
-
H. Abdulhaq, J. Rossetti (2007)
The role of azacitidine in the treatment of myelodysplastic syndromesExpert Opinion on Investigational Drugs, 16
-
E. Feldman, K. Seiter, T. Ahmed, P. Baskind, Z. Arlin (1996)
Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.Leukemia, 10 1
-
Obrien (1993)
A555Blood, 82
-
H. Jie, D. He, Xingkui Xue, Gao Liang, Wenjun Wu, Xiaoyan Han, Cai Zhen (2007)
Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathwayLeukemia & Lymphoma, 48
-
E. Plimack, H. Kantarjian, J. Issa (2007)
Decitabine and its role in the treatment of hematopoietic malignanciesLeukemia & Lymphoma, 48
-
M. Fresno, A. Jimenez, D. Vazquez (1977)
Inhibition of translation in eukaryotic systems by harringtonine.European journal of biochemistry, 72 2
-
Coonley (1983)
136Proceedings of the American Association for Cancer Research, 24
-
Huang (1975)
511Molecular Pharmacology, 11
-
Feldman (1996)
40Leukemia, 10
-
E. Atallah, G. Garcia-Manero (2008)
Treatment Strategies in Myelodysplastic SyndromesCancer Investigation, 26
-
K. Kuliczkowski (1989)
Influence of harringtonine on human leukemia cell differentiation.Archivum immunologiae et therapiae experimentalis, 37 1-2
-
C. Tan, E. Luks, D. Bacha, P. Steinherz, L. Steinherz, A. Mondora (1987)
Phase I trial of homoharringtonine in children with refractory leukemia.Cancer treatment reports, 71 12
-
Coonley Cj, Warrell Rp, Charles Young (1983)
Phase I trial of homoharringtonine administered as a 5-day continuous infusion.Cancer treatment reports, 67 7-8
-
G. Visani, D. Russo, E. Ottaviani, P. Tosi, D. Damiani, A. Michelutti, S. Manfroi, M. Baccarani, S. Tura (1997)
Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on ‘in vitro’ growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitorsLeukemia, 11
-
Junfeng Liu, Yong Lin, W. Shih (2010)
On Simon's two‐stage design for single‐arm phase IIA cancer clinical trials under Beta‐binomial distributionStatistics in Medicine, 29
-
B. Cheson, John Bennett, K. Kopecky, T. Büchner, C. Willman, E. Estey, Charles Schiffer, H. Doehner, Martin Tallman, T. Lister, F. Lo‐Coco, R. Willemze, A. Biondi, W. Hiddemann, Richard Larson, B. Löwenberg, M. Sanz, David Head, R. Ohno, Clara Bloomfield (2003)
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 24
-
Bian Sg, Hao Ys, Wang Zc (1990)
[Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia].Zhonghua nei ke za zhi, 29 1
-
A. Kornblith, J. Herndon, L. Silverman, E. Demakos, R. Odchimar-Reissig, J. Holland, B. Powell, C. Decastro, J. Ellerton, R. Larson, C. Schiffer, J. Holland (2002)
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 10
-
R. Tujebajeva, D. Graifer, Galina Karpova, N. Ajtkhozhina (1989)
Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formationFEBS Letters, 257
-
S. O’Brien, H. Kantarjian, Michael Keating, M. Beran, C. Koller, L. Robertson, Jeane Hester, M. Rios, Michael Andreeff, Moshe Talpaz (1995)
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.Blood, 86 9
-
C.J. Coonley, R.P. Warrell, C.W. Young (1983)
Phase‐I trial of homoharringtonine administered as a 5 day continuous infusionProceedings of the American Association for Cancer Research, 24
-
H. Kantarjian, M. Talpaz, V. Santini, A. Murgo, B. Cheson, S. O'brien (2001)
Homoharringtonine: History, current research, and future directionsCancer, 92
-
P. Greenberg, C. Cox, M. Lebeau, P. Fenaux, P. Morel, G. Sanz, M. Sanz, T. Vallespí, T. Hamblin, D. Oscier, K. Ohyashiki, K. Toyama, C. Aul, G. Mufti, John Bennett (1997)
International scoring system for evaluating prognosis in myelodysplastic syndromes.Blood, 89 6
-
Eric Feldman, Z. Arlin, Tauseef Ahmed, A. Mittelman, C. Puccio, H. Chun, P. Cook, P. Baskind (1992)
Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.Leukemia, 6 11
-
R. Warrell, C. Coonley, T. Gee (1985)
Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 3 5
-
A. Quintás-Cardama, J. Cortes (2008)
Homoharringtonine for the treatment of chronic myelogenous leukemiaExpert Opinion on Pharmacotherapy, 9
-
H. Kantarjian, J.P. Issa, C.S. Rosenfeld, J.M. Bennett, M. Albitar, J. Dipersio, V. Klimek, J. Slack, C. Castro, F. Ravandi, R. Helmer, L. Shen, S.D. Nimer, R. Leavitt, A. Raza, H. Saba (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyCancer, 106
-
A. Quintás-Cardama, J. Cortes (2008)
Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.IDrugs : the investigational drugs journal, 11 5
-
(1976)
Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment.Chinese medical journal, 2 4
-
A. Barrett, B. Savani (2008)
Allogeneic stem cell transplantation for myelodysplastic syndrome.Seminars in hematology, 45 1
-
J.Y. Zhou, D.L. Chen, Z.S. Shen, H.P. Koeffler (1990)
Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitroCancer Research, 50
-
Boyd (1984)
384Blood, 63
-
Feldman (1992b)
1185Leukemia, 6
-
Jian-Yuan, Zhou Chen, Zenxin Shen, H. Koeffler (2006)
in Vitro of Human Leukemic Cells Effect of Homoharringtonine on Proliferation and Differentiation -
Li (1983)
303Chinese Medical Journal, 96
-
H. Kantarjian, M. Keating, R. Walters, C. Koller, K. McCredie, E. Freireich (1989)
Phase II study of low‐dose continuous infusion homoharringtonine in refractory acute myelogenous leukemiaCancer, 63
-
H. Kantarjian, J. Issa, C. Rosenfeld, J. Bennett, M. Albitar, J. Dipersio, V. Klimek, J. Slack, Carlos Castro, F. Ravandi, Richard Helmer, Lanlan Shen, S. Nimer, R. Leavitt, A. Raza, H. Saba (2006)
Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 106
-
Y. Takemura, T. Ohnuma, T. Chou, T. Okano, J. Holland (2004)
Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cellsCancer Chemotherapy and Pharmacology, 14
-
L. Silverman, E. Demakos, B. Peterson, A. Kornblith, J. Holland, R. Odchimar-Reissig, R. Stone, D. Nelson, B. Powell, C. Decastro, J. Ellerton, R. Larson, C. Schiffer, J. Holland (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 10
-
Bian (1990)
22Zhonghua Nei Ke Za Zhi, 29
-
Tan (1987)
1245Cancer Treatment Reports, 71
-
J. Ajani, I. Dimery, Sant Chawla, K. Pinnamaneni, R. Benjamin, S. Legha, I. Krakoff (1986)
Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas.Cancer treatment reports, 70 3
-
Kuliczkowski (1989)
69Archivum Immunologiae et Therapiae Experimentalis, 37
-
Quintas-Cardama (2008b)
356IDrugs, 11
-
A. Boyd, J. Sullivan (1984)
Leukemic cell differentiation in vivo and in vitro: arrest of proliferation parallels the differentiation induced by the antileukemic drug Harringtonine.Blood, 63 2
-
Feldman (1992a)
1189Leukemia, 6
- Publisher
- Wiley
- Copyright
- Copyright © 2013 John Wiley & Sons Ltd
- ISSN
- 0961-5423
- eISSN
- 1365-2354
- DOI
- 10.1111/ecc.12065
- pmid
- 23701251
- Publisher site
- See Article on Publisher Site
Abstract
Homoharringtonine is an alkaloid inhibitor of protein synthesis with activity in myeloid malignancies. We report a phase II pilot study of homoharringtonine in myelodysplastic syndrome (MDS). Induction consisted of homoharringtonine at 2.5 mg/m2 via continuous infusion for 7 days. Maintenance was given every 4 weeks. Nine patients were enrolled: five with refractory anaemia with excess blasts, two with refractory anaemia with excess blasts in transformation, one each with refractory anaemia and chronic myelomonocytic leukaemia respectively. Median age was 70 years (55–84) and 6 (66%) were male. Per International Prognostic Scoring System (IPSS) two patients were intermediate‐1, five intermediate‐2 and two high‐risk. Median chemotherapy courses were one (1–3). One patient (11%) responded with complete haematological and cytogenetic remission after one course. Eight patients did not respond (four had stable disease, two progressed to acute leukaemia and two died during induction – from aspergillus pneumonia and intracerebral haemorrhage respectively). Grade 3/4 myelosuppression seen in 56% (5/9). Serious non‐haematological toxicities included one case of grade 4 left bundle branch heart block and one grade 3 nephrotoxicity. Median time between courses was 42 days (35–72 days). In conclusion homoharringtonine might have clinical activity in some patients with MDS.
Journal
European Journal of Cancer Care – Wiley
Published: Jan 1, 2013
Keywords: ; ; ; ;